Tesamorelin
Tesamorelin Acetate
An FDA-approved GHRH analog primarily used for reducing visceral fat. One of the few peptides with robust clinical trial data in humans for body composition improvement.
How Tesamorelin Works
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and secrete endogenous growth hormone. It is the only GHRH analogue with FDA approval (for HIV-associated lipodystrophy), which gives it a stronger regulatory evidence base than most peptides. It selectively reduces visceral adipose tissue (deep belly fat) by increasing lipolysis while preserving subcutaneous fat and lean mass, making it particularly effective for metabolic health and body recomposition.
📊 Evidence by Outcome
FDA-approved for HIV-associated lipodystrophy. Strong human data showing significant visceral fat reduction.
12 studies • Consistency: High • Effect: Large
Reduces trunk fat while preserving lean mass. Effects are dose-dependent.
8 studies • Consistency: High • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 3 Citations
Tesamorelin reduces visceral fat and improves body composition in HIV-infected patients
Falutz J et al.•N Engl J Med•2007•PMID: 17942874
Key Finding: Tesamorelin achieved 15.2% reduction in visceral adipose tissue vs placebo, with improvements in triglycerides and body image.
View on PubMedTesamorelin, a GHRH analog, reduces liver fat and fibrosis in HIV-associated NAFLD
Stanley TL et al.•J Clin Invest•2021•PMID: 33855975
Key Finding: Tesamorelin significantly reduced hepatic fat fraction and prevented liver fibrosis progression in a randomized controlled trial.
View on PubMedEffects of tesamorelin on body composition, visceral fat and metabolic parameters
Dhillon S•Drugs•2011•PMID: 21548606
Key Finding: FDA-approved tesamorelin demonstrated consistent visceral fat reduction across multiple phase III trials with minimal adverse effects.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
Side Effects & Safety
Interactions & Contraindications
Drug Interactions
- •Interacts with diabetes medications (may increase blood glucose; insulin or oral hypoglycemics may need adjustment)
- •May interact with corticosteroids (both affect GH axis and glucose metabolism)
- •Caution with antiretroviral drugs — originally developed for HIV-associated lipodystrophy
Supplement Interactions
- •May work synergistically with L-carnitine for fat metabolism
- •Compatible with omega-3 fatty acids for metabolic health
- •Chromium supplementation may help counteract glucose effects
Food & Timing
- •Inject on an empty stomach for optimal GH release
- •Avoid high-glycemic meals close to injection time
- •Morning injection is standard protocol
Who Should Avoid
- •Active cancer or history of malignancy (stimulates GH which promotes cell growth)
- •Disruption of the hypothalamic-pituitary axis (head trauma, hypophysectomy, pituitary surgery/radiation)
- •Known hypersensitivity to tesamorelin or mannitol
- •Pregnancy (FDA Category X — can cause fetal harm)
- •Uncontrolled diabetes
- •Active retinopathy
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
AED 1,500-3,500/month
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Frequently Asked Questions
Tesamorelin is available through select wellness clinics and compounding pharmacies in the UAE. Being FDA-approved (as Egrifta) for a specific indication, it may also be available through some hospital pharmacies. A clinical consultation is required.
Clinical studies show significant reduction in visceral fat within 12-26 weeks. Some users notice body composition improvements and improved energy as early as 6-8 weeks.
Tesamorelin is FDA-approved with more robust clinical trial data, particularly for visceral fat reduction. It works through the GHRH pathway only, whereas CJC-1295/Ipamorelin combines GHRH and ghrelin receptor pathways for a broader GH response. Tesamorelin may be preferred for patients wanting a more evidence-backed option.
Yes. Baseline IGF-1, fasting glucose, HbA1c, and a metabolic panel are recommended. Regular monitoring every 3 months is standard practice during treatment.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.